IRADIMED Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

IRADIMED heeft een totaal eigen vermogen van $83.4M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $94.2M en $10.8M. De EBIT IRADIMED is $21.3M waardoor de rentedekking -11.4 is. Het heeft contanten en kortetermijnbeleggingen van $51.7M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio	-11.4x
Contant	US$51.72m
Aandelen	US$83.43m
Totaal verplichtingen	US$10.81m
Totaal activa	US$94.25m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

Aug 08

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Feb 23

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Feb 05

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Oct 10

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Aug 23

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Aug 17

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

Jul 29

IRadimed: Reduce Equity Beta With Upside Capture

Jul 18

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Jul 13

At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Feb 05

Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Jan 12

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $74.3M ) IRMD } overtreffen de korte termijn passiva ( $8.1M ).

Langlopende schulden: De kortetermijnactiva IRMD ( $74.3M ) overtreffen de langetermijnschulden ( $2.8M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: IRMD is schuldenvrij.

Schuld verminderen: IRMD had 5 jaar geleden geen schulden.

Schuldendekking: IRMD heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: IRMD heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

IRADIMED Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Iradimed Corporation Revises Earnings Guidance for the Year 2024

IRADIMED CORPORATION to Report Q3, 2024 Results on Oct 31, 2024

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

IRADIMED CORPORATION Declares A Regular Quarterly Cash Dividend, Payable on August 30, 2024

IRADIMED CORPORATION to Report Q2, 2024 Results on Aug 01, 2024

Independent Director recently sold US$84k worth of stock

Upcoming dividend of US$0.15 per share

IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend, Payable on May 30, 2024

Now 25% overvalued

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024

Now 21% overvalued

Now 21% overvalued after recent price rise

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024

Director notifies of intention to sell stock

IRadimed Corporation Approves Initiation of Regular Quarterly Dividend, Payable on January 12, 2024

Director notifies of intention to sell stock

Independent Director recently sold US$122k worth of stock

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023

Founder notifies of intention to sell stock

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Price target increased by 9.5% to US$57.50

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Independent Director recently sold US$128k worth of stock

Price target increased by 14% to US$52.50

IRadimed Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 16%

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023

IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023

Investor sentiment improves as stock rises 16%

Price target increased to US$46.00

IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023

Independent Director exercised options to buy US$87k worth of stock.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

IRadimed Corporation to Report Q3, 2022 Results on Nov 03, 2022

IRadimed Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

IRadimed Corporation Announces Board Changes

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Investor sentiment deteriorated over the past week

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Independent Director recently sold US$116k worth of stock

Insufficient new directors

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

IRadimed Corporation to Report Q2, 2022 Results on Jul 29, 2022

IRadimed: Reduce Equity Beta With Upside Capture

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Insufficient new directors

IRadimed Corporation Names John F. Glenn as Chief Financial Officer, Effective on or before June 20, 2022

Price target decreased to US$40.00

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$53.00

IRadimed Corporation to Report Q1, 2022 Results on Apr 29, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS exceeds analyst expectations

Independent Director notifies of intention to sell stock

COO, CFO & Secretary recently sold US$965k worth of stock

Investor sentiment improved over the past week